Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Roundtable
43 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
COVID-19 Impacts
Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?
PAP-Q4-20-NI-006
Roundtable
Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?
PAP-Q4-20-NI-007
Post COVID-19 Supply Chain
Q: How are you rethinking your supply chain and operational fitness in light of the COVID-19 pandemic?
PAP-Q3-20-NI-007
Roundtable
Q: What steps is your company taking to address drug pricing issues?
PAP-Q3-20-NI-008
COVID-19
Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?
PAP-Q2-20-RT-001
Roundtable
Q: What two or three drug molecules do you identify as having had the greatest impact on society? What about on the pharmaceutical industry?
PAP-Q2-20-RT-002
M&A
Q: How would you characterize the current landscape of M&A activity in the pharmaceutical/biopharmaceutical industry?
PAP-Q1-20-NI-008
Technology
Q: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?
PAP-Q1-20-NI-009
Technology
Q: What developing technologies do you believe will have the greatest impact on the biopharma industry in 2020 and beyond?
PAP-Q4-19-NI-006
Technology
Q: What breakthrough technologies have had a transformative effect on your business this year?
PAP-Q4-19-NI-005
Manufacturing Technology
Q: How does your company manage to provide local services/support while still efficiently managing global compliance?
PAP-Q2-19-NI-006
Novel Therapies
Q: What do you identify as the greatest advances that have been achieved in recent years with respect to harmonization of pharmaceutical regulations?
PAP-Q2-19-NI-007
Manufacturing Technology
Q: What advances in manufacturing technology are most enabling the scale-up and commercialization of next-generation therapies?
PAP-Q2-2019-NI-006
Novel Therapies
Q: What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?
PAP-Q2-2019-NI-007
Ethical Business Practices
Q: Given the ongoing evolution of the pharma industry today, how does your organization incorporate ethical concerns into your business practices?
PAP-Q1-2019-NI-001
Artificial Intelligence
Q: What do you believe the role of artificial intelligence and other advanced technologies will be in driving the development of the pharmaceutical industry over the next decade?
PAP-Q1-2019-NI-002
Roundtable
Q: What Innovative Technologies Had the Greatest Impact on your Company this Year? What Were the Impacts?
PAP-Q4-18-NI-007
Roundtable
Q: Looking Forward, What New Technologies/Paradigms Do You Anticipate Having the Greatest Impact Next Year (Digitalization and Industry 4.0, Serialization, etc.)?
PAP-Q4-18-NI-003
Q: What Role has M&A Played in your Company’s Growth?
Roundtable
Q: How do you Address Operational Excellence as an Institution?
PAP-Q4-17-RT-002
Roundtable
Q: Looking forward, what technologies do you anticipate having the greatest impact in 2018?
PAP-Q4-17-RT-002
Roundtable
Q: What do you see as being the most innovative technologies introduced in 2017? Why were they important? What impacts did they have?
PAP-Q4-17-RT-001
Roundtable
Q: How important are international partnerships (with sponsor firms, service providers, engineering firms, equipment vendors, raw material suppliers, etc.) to your success?
PAP-Q3-17-RT-001
Biologic
Q: If You Could Have One Piece of Biologic Manufacturing Equipment Improved, What Would It Be and Why?
PAP-Q2-17-RT-001
1
2
»
